ProQR Therapeutics N.V (PRQR) concluded trading on Wednesday at a closing price of $2.62, with 0.44 million shares of worth about $1.15 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 53.22% during that period and on January 08, 2025 the price saw a loss of about -1.13%. Currently the company’s common shares owned by public are about 81.68M shares, out of which, 74.28M shares are available for trading.
Stock saw a price change of -1.13% in past 5 days and over the past one month there was a price change of -26.40%. Year-to-date (YTD), PRQR shares are showing a performance of -1.13% which increased to 31.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.61 but also hit the highest price of $4.62 during that period. The average intraday trading volume for ProQR Therapeutics N.V shares is 1.56 million. The stock is currently trading -5.60% below its 20-day simple moving average (SMA20), while that difference is down -20.64% for SMA50 and it goes to 11.85% higher than SMA200.
ProQR Therapeutics N.V (NASDAQ: PRQR) currently have 81.68M outstanding shares and institutions hold larger chunk of about 17.68% of that.
The stock has a current market capitalization of $270.39M and its 3Y-monthly beta is at 0.28. It has posted earnings per share of -$0.32 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 0.63. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRQR, volatility over the week remained 6.69% while standing at 9.67% over the month.
Stock’s fiscal year EPS is expected to rise by 2.34% while it is estimated to decrease by -19.92% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on October 29, 2024 offering a Strong buy rating for the stock and assigned a target price range of between $6 and $14 to it. Coverage by Chardan Capital Markets stated ProQR Therapeutics N.V (PRQR) stock as a Buy in their note to investors on November 08, 2023, suggesting a price target of $2 for the stock. On March 30, 2023, JMP Securities Upgrade their recommendations, while on December 22, 2022, Cantor Fitzgerald Upgrade their ratings for the stock with a price target of $5. Stock get a Neutral rating from Citigroup on February 14, 2022.
